Afrezza Inhaled Insulin for Pediatric Diabetes

Afrezza Inhaled Insulin for Pediatric Diabetes
80%69%58%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 21 • YES 62.0%May 22 • YES 62.0%May 24 • YES 76.2%May 27 • YES 66.4%
Mannkind Corporation ($MNKD)
No stock close$3.64$3.26$2.87May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • MNKD $2.99May 19 • MNKD $2.96May 20 • MNKD $3.25May 21 • MNKD $3.31May 22 • MNKD $3.38May 26 • MNKD $3.53May 27 • MNKD $3.55

Will this trial show a positive result on change in HbA1c?

Paper Trading
Create account to trade

Matched news3 items

All news
MNKD

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led research in pregnancy Late-breaking comparative data vs. rapid-acting insulin analogs to be presented June 7 Nine posters showcase new clinical and real-world

Presentation / AbstractADA poster presentations Sat, Jun 6, 2026, 12:30 PM CTMatched afrezza, inhaled, insulin, pediatric, diabetes
MNKD

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference

Presentation / AbstractMatched afrezza, inhaled, insulin, pediatric, diabetes